In 222 treated adults with gastric cancer and peritoneal metastasis (238 randomised 2:1), adding intraperitoneal paclitaxel to intravenous paclitaxel plus S-1 improved median overall survival: 19.4 vs 13.9 months (HR 0.67), with similar grade 3–4 adverse events.
RCTn = 238
Yan et al. Intraperitoneal and Intravenous Paclitaxel Plus S-1 for Gastric Cancer With Peritoneal Metastasis: A Phase 3 Randomized Clinical Trial